The speed of technological advancements in the life sciences industry is forcing patent lawyers to consider whether the norms they’re used to dealing with in the profession still apply.
Technology company IBM is seeking to patent the use of blockchain in open scientific research, including experiments, data collection, and analysis.
Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.
Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.
A jury has said that Flexus Biosciences, a company owned by Bristol-Myers Squibb, does not need to pay damages despite being liable for trade secrets misappropriation.
The strongest cannabidiol patent portfolios are owned by Roche, Boehringer Ingelheim, and AbbVie, according to a report released earlier this week.
The European Patent Office has revoked a Bayer-owned patent which covers a type of broccoli adapted to make their harvesting easier.
Biotech company Momenta has obtained the rights to use AbbVie’s Humira IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.
Womble Bond Dickinson has strengthened its Boston-based life sciences team with the addition of patent attorney Briana Erickson.
Pfizer has entered into an oncology collaboration with Nektar Therapeutics, a US development stage biopharma company.